Medicinefrom24/7 Wall St.5 days agoNeurocrine Biosciences Beats Estimates But Wall Street Punishes The StockNeurocrine Biosciences delivered a strong Q3 earnings beat driven by INGREZZA growth and advancing clinical pipeline programs.